{"id":331366,"date":"2025-05-15T16:42:02","date_gmt":"2025-05-15T21:42:02","guid":{"rendered":"https:\/\/www.liveaction.org\/news\/?p=331366"},"modified":"2025-05-15T15:16:30","modified_gmt":"2025-05-15T20:16:30","slug":"hhs-kennedy-fda-review-abortion-pill-risks","status":"publish","type":"post","link":"https:\/\/archive.liveaction.org\/news\/hhs-kennedy-fda-review-abortion-pill-risks\/","title":{"rendered":"HHS Secretary Robert F. Kennedy Jr. asks FDA for ‘complete review’ of abortion pill risks"},"content":{"rendered":"
<\/div>

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced Wednesday that he believes the Food and Drug Administration (FDA) should conduct a “complete review” of the abortion pill. The announcement comes after a recent analysis<\/a> of insurance data published by the Ethics and Public Policy Center (EPPC) stated that “serious adverse events” (complications) of the abortion pill (mifepristone) occur at a rate far higher than the rate reported on the FDA’s drug label.<\/p>\n

As reported<\/a> by Live Action News:<\/p>\n

[According to the EPPC,] nearly 11% of women<\/strong>\u00a0(10.93%) experience sepsis, infection, hemorrhaging, or other serious or life-threatening adverse events following a mifepristone abortion. This means\u00a0one in ten women<\/strong>\u00a0experience at least one serious complication from taking mifepristone within 45 days \u2014 22 times higher than the \u201cless than 0.5 percent\u201d serious adverse events rate reported by the FDA on the mifepristone label, according to this study. <\/em><\/p>\n

The study authors state that serious adverse events in multiple categories were accounted for in the reported rate.<\/em><\/p>\n

Research from the EPPC also claims that the failure rate of mifepristone is nearly double<\/a> the failure rate currently listed on the FDA-approved drug label. Though the FDA label asserts a 2.6-3.8% failure rate for mifepristone abortions, the EPPC’s analysis states that real-world data shows a failure rate of 5.26.<\/p>\n

Kennedy’s comments came during a Senate Health, Education, Labor, and Pensions Committee hearing, when Senator Josh Hawley referenced the EPPC report and asked Kennedy if he would look into the study’s findings.<\/p>\n

\n
\n

RFK Jr. says he has asked FDA to do a thorough review of mifepristone in light of a study indicating serious side effects could be 22x more common than the FDA says pic.twitter.com\/kHLNGqsdeA<\/a><\/p>\n

— Emily Kopp (@emilyakopp) May 14, 2025<\/a><\/p><\/blockquote>\n